Lentivirus is challenging to manufacture. Unwanted transgene expression and viral genome instability are two common and critical issues. Lentitek can help you solve these challenges through a combination of expert design services and the incorporation of our unique manufacturing technology, which effectively eliminates unwanted transgene expression by stabilising the vector genome during the manufacturing process. Our approach enables you to optimise vector performance, enhance quality and safety, and minimise potentially hazardous off-target effects.
| Website | http://www.lentitek.com |
| Employees | 10 (3 on RocketReach) |
| Founded | 2019 |
| Industry | Biotechnology Research |
| Keywords | Cell Therapy, Gene Therapy, Advanced Therapies, Therapeutics, Immunotherapy, Cell Engineering, Oncology, Regenerative Medicine, Clinical Trials, Precision Medicine, Genetic Engineering, Drug Development, Biotechnology, Pharmaceutical, Biologics, Bioprocessing, Pharmaceutical Development, Healthcare |
| Competitors | Biocon, Lonza, Sartorius, Thermo Fisher Scientific, Merck Group, Boehringer Ingelheim, Genentech, Pfizer, Roche, AbbVie +43 more (view full list) |
Looking for a particular Lentitek employee's phone or email?
Lentitek Questions
Adam Inche is the Founder of Lentitek.
3 people are employed at Lentitek.
Lentitek is based in Edinburgh, Scotland.
Top Lentitek Employees
-
Adam Inche
Founder at Lentitek
Edinburgh, Scotland, GB2 -
1
-
11
Related Companies
